The Rise and Fall of Bluebird Bio

This chapter examines the vibrant imagery of a political event before shifting focus to the dramatic acquisition of Bluebird Bio by Carlyle and SK Capital, signaling a significant drop from its former valuation. It explores the company's struggles with financing and commercialization in the gene therapy sector, highlighting the impact of competition and management decisions. The discussion also touches on the ramifications of private equity ownership and its potential effects on the development of Bluebird's therapies amidst pricing challenges in the healthcare landscape.